Pieris Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Note 7 - Accrued Expenses

9 Months Ended

Sep. 30, 2022

7. Accrued Expenses

Accrued expenses and other current liabilities consisted of the following (in thousands):

	*September 30,*		*December 31,*
	*2022*		*2021*
Research and development fees	$	5,036	$	5,682
Compensation expense		3,248		3,581
Accrued license obligations		131		1,541
Accrued accounts payable		1,560		2,980
Lease liabilities		826		1,049
Other current liabilities		581		393
Collaboration cost-sharing obligation		—		1,610
Total	$	11,382	$	16,836